Merrimack Pharmaceuticals

Investors
- Press Releases
- Events & Presentations
- Corporate Governance
- Overview
- Board of Directors
- Committee Composition
- Board Diversity Matrix
- SEC Filings
- Stock Information
- Stock Quote & Chart
- Historic Stock Lookup
- Investment Calculator
- Investor FAQs
- Contact IR
Contact

Engineering and Preclinical Activity of MM-201, a Potentially Best-in-Class TRAIL Receptor Agonist

Press Release

Engineering and Preclinical Activity of MM-201, a Potentially Best-in-Class TRAIL Receptor Agonist

Back to top

One Broadway, 14th floor
Cambridge, MA 02142
617-720-8606
info@merrimack.com

Privacy Policy
Terms of Use
Contact

© 2023 Merrimack.